LHLily Hoa

Lily Hoa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lily Hoa has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Adrienne Morgan

    Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, London, EC1M 6BQ, UK

    1 shared publication
  • Emily A. Saunderson

    Centre for Haemato-Oncology, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, United Kingdom

    1 shared publication
  • Gabriella Ficz

    Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK

    1 shared publication
  • J. Louise Jones

    Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, London, EC1M 6BQ, UK

    1 shared publication
  • Jennifer J. Gomm

    Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, London, EC1M 6BQ, UK

    1 shared publication
  • John G. Gribben

    Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, London, EC1M 6BQ, UK

    1 shared publication

Latest Publications

  • Open Access

    Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors

    by Emily A. Saunderson, Peter Stepper, Jennifer J. Gomm, Lily Hoa, Adrienne Morgan, Michael D. Allen, J. Louise Jones, John G. Gribben, Tomasz P. Jurkowski, Gabriella Ficz

    Aberrant promoter DNA hypermethylation is a hallmark of cancer; however, whether this is sufficient to drive cellular transformation is not clear. To investigate this question, we use a CRISPR-dCas9 epigenetic editing tool, where an inactive form of Cas9 is fused to DNA methyltransferase effectors. Using this system, here we show simultaneous de novo DNA methylation of genes commonly methylated in cancer, CDKN2A, RASSF1, HIC1 and PTEN in primary breast cells isolated from healthy human breast tissue. We find that promoter methylation is maintained in this system, even in the absence of the fusion construct, and this prevents cells from engaging senescence arrest. Our data show that the key driver of this phenotype is repression of CDKN2A transcript p16 where myoepithelial cells harbour cancer-like gene expression but do not exhibit anchorage-independent growth. This work demonstrates that hit-and-run epigenetic events can prevent senescence entry, which may facilitate tumour initiation.